International Stem Cell CORP (ISCO)
About International Stem Cell CORP
INTL STEM CELL CORP
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.1M
- Net income
- -$418.0K
- Total assets
- $4.8M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
International Stem Cell CORP (ISCO) Stock Price
- Reported a net loss of $418.0K in FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review International Stem Cell CORP.
Write a review
International Stem Cell CORP: frequently asked questions
Is International Stem Cell CORP an American company?
International Stem Cell CORP is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is International Stem Cell CORP headquartered?
International Stem Cell CORP is headquartered in San Diego, California, United States.
Is International Stem Cell CORP publicly traded?
Yes — International Stem Cell CORP is a publicly traded company. Its stock trades under the ticker symbol ISCO on the OTC.
What does International Stem Cell CORP do?
International Stem Cell CORP is an American Pharmaceuticals company in the Health & Beauty sector.
